Recent Updates
Recently added Catalysts
MNKD

MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference

Key Takeaway: VALENCIA, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, will present today at the 35th Annual J.P. Morgan Healthcare Conference at 10:00 AM (PST) at the West

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

VALENCIA, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, will present today at the 35th Annual J.P. Morgan Healthcare Conference at 10:00 AM (PST) at the Westin St. Francis Hotel in San Francisco, California.
Presenting from the Company will be its Chief Executive Officer, Matthew J. Pfeffer.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Last updated: Jan 5, 2017